Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion

  • Yeo Jue Byun
  • Mi In Roh
  • Sung Chul Lee
  • Hyoung Jun KohEmail author
Retinal Disorders



To compare visual outcomes after intravitreal triamcinolone acetonide (IVTA) injection and intravitreal bevacizumab (IVB) administration for treatment of macular edema associated with branch retinal vein occlusion (BRVO).


A retrospective comparative case series of 134 consecutive patients that were treated with either IVTA or IVB for macular edema caused by BRVO. Visual acuity at baseline and 1, 3, 6, 9, and 12 months, and central macular thickness measured by OCT at baseline and 1, 3, 6, and 12 months. The time to recurrence of macular edema after treatment was also analyzed.


Visual acuity (Snellen equivalent) improved significantly from 0.87 logMAR (0.14) to 0.49 logMAR (0.33) in the IVTA group, and from 0.91 logMAR (0.13) to 0.45 logMAR (0.36) in the IVB group 12 months after injection (p < 0.001). Central macular thickness decreased significantly from 491.0 μm to 255.8 μm in the IVTA group, and from 477.4 μm to 218.9 μm in the IVB group 12 months after injection (p < 0.001). In between-group comparisons, neither visual acuity (p = 0.892) nor macular thickness (p = 0.612) improvements were statistically significantly different. In the IVTA-all group, recurrence of macular edema occurred in 7.6% of patients at a mean of 12.6 months postoperatively, and the average number of injections was 1.08. In the IVB-all group, 26.0% of patients suffered recurrences at a mean of 5.3 months after treatment, and received a mean of 1.89 injections. Recurrence was more frequent in the IVB group compared to the IVTA group (Kaplan–Meier survival analysis log-rank test, p < 0.0001).


IVTA and IVB injections were similarly effective for improving visual acuity in patients with macular edema secondary to BRVO. However, the IVTA group showed longer mean improvement duration and less disease recurrence, and required fewer injections than the IVB group.


Bevacizumab Branch retinal vein occlusion Triamcinolone acetonide 


  1. 1.
    Ryan SJ (2001) Retina. Mosby, St. LouisGoogle Scholar
  2. 2.
    Mitchell P, Smith W, Chang A (1996) Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 114:1243–1247PubMedGoogle Scholar
  3. 3.
    The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98:271–282Google Scholar
  4. 4.
    Finkelstein D (1992) Ischemic macular edema. Recognition and favorable natural history in branch vein occlusion. Arch Ophthalmol 110:1427–1434PubMedGoogle Scholar
  5. 5.
    Greer DV, Constable IJ, Cooper RL (1980) Macular oedema and retinal branch vein occlusion. Aust J Ophthalmol 8:207–209CrossRefPubMedGoogle Scholar
  6. 6.
    Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 127:1115–1128CrossRefPubMedGoogle Scholar
  7. 7.
    Hou J, Tao Y, Jiang YR, Li XX, Gao L (2009) Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study. Chin Med J (Engl) 122:2695–2699Google Scholar
  8. 8.
    Cheng KC, Wu WC, Chen KJ (2009) Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion. Eye (Lond) 23:2023–2033Google Scholar
  9. 9.
    Jaissle GB, Ziemssen F, Petermeier K, Szurman P, Ladewig M, Gelisken F, Volker M, Holz FG, Bartz-Schmidt KU (2006) Bevacizumab for treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 103:471–475CrossRefPubMedGoogle Scholar
  10. 10.
    Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL (2007) Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27:419–425CrossRefPubMedGoogle Scholar
  11. 11.
    Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P (2009) One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 247:27–33CrossRefPubMedGoogle Scholar
  12. 12.
    Kogure A, Ohkoshi K, Kogure S, Yamaguchi T, Kishi S (2008) Efficacy and retention times of intravitreal triamcinolone acetonide for macular edema. Jpn J Ophthalmol 52:122–126CrossRefPubMedGoogle Scholar
  13. 13.
    Kreutzer TC, Alge CS, Wolf AH, Kook D, Burger J, Strauss R, Kunze C, Haritoglou C, Kampik A, Priglinger S (2008) Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 92:351–355CrossRefPubMedGoogle Scholar
  14. 14.
    Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T, Nishida K (2008) Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 145:854–861CrossRefPubMedGoogle Scholar
  15. 15.
    Jonas JB, Degenring R, Kreissig I, Akkoyun I (2004) Safety of intravitreal high-dose reinjections of triamcinolone acetonide. Am J Ophthalmol 138:1054–1055CrossRefPubMedGoogle Scholar
  16. 16.
    Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA (2005) Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 112:593–598CrossRefPubMedGoogle Scholar
  17. 17.
    Ozkiris A, Evereklioglu C, Erkilic K, Dogan H (2006) Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion. Eye 20:13–17CrossRefPubMedGoogle Scholar
  18. 18.
    Wu L, Arevalo JF, Roca JA, Maia M, Berrocal MH, Rodriguez FJ, Evans T, Costa RA, Cardillo J (2008) Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 28:212–219CrossRefPubMedGoogle Scholar
  19. 19.
    Avitabile T, Longo A, Reibaldi A (2005) Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 140:695–702PubMedGoogle Scholar
  20. 20.
    Oh JY, Seo JH, Ahn JK, Heo JW, Chung H (2007) Early versus late intravitreal triamcinolone acetonide for macular edema associated with branch retinal vein occlusion. Korean J Ophthalmol 21:18–20CrossRefPubMedGoogle Scholar
  21. 21.
    Prager F, Michels S, Kriechbaum K, Georgopoulos M, Funk M, Geitzenauer W, Polak K, Schmidt-Erfurth U (2009) Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 93:452–456CrossRefPubMedGoogle Scholar
  22. 22.
    Lee H, Shah GK (2005) Intravitreal triamcinolone as primary treatment of cystoid macular edema secondary to branch retinal vein occlusion. Retina 25:551–555CrossRefPubMedGoogle Scholar
  23. 23.
    Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M (2003) Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 110:681–686CrossRefPubMedGoogle Scholar
  24. 24.
    Krohne TU, Eter N, Holz FG, Meyer CH (2008) Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 146:508–512CrossRefPubMedGoogle Scholar
  25. 25.
    Fong KC, Kirkpatrick N, Mohamed Q, Johnston RL (2008) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment. Clin Exp Ophthalmol 36:748–755CrossRefGoogle Scholar
  26. 26.
    Melamud A, Stinnett S, Fekrat S (2008) Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Am J Ophthalmol 146:91–95CrossRefPubMedGoogle Scholar
  27. 27.
    Patel PJ, Zaheer I, Karia N (2008) Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion. Eye 22:60–64CrossRefPubMedGoogle Scholar
  28. 28.
    Stahl A, Agostini H, Hansen LL, Feltgen N (2007) Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 245:1429–1436CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Yeo Jue Byun
    • 1
  • Mi In Roh
    • 1
  • Sung Chul Lee
    • 1
  • Hyoung Jun Koh
    • 1
    Email author
  1. 1.The Institute of Vision Research, Department of OphthalmologyYonsei University College of MedicineSeoulKorea

Personalised recommendations